Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Progyny (PGNY) and Wave Life Sciences (WVE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report), Progyny (PGNY – Research Report) and Wave Life Sciences (WVE – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teleflex (TFX)
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Teleflex. The company’s shares closed last Thursday at $119.02.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Currently, the analyst consensus on Teleflex is a Hold with an average price target of $127.50, implying a 17.5% upside from current levels. In a report released yesterday, RBC Capital also maintained a Hold rating on the stock with a $125.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Progyny (PGNY)
Truist Financial analyst Jailendra Singh maintained a Buy rating on Progyny today. The company’s shares closed last Thursday at $22.25.
According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $30.33, which is a 42.9% upside from current levels. In a report issued on February 23, Barclays also maintained a Buy rating on the stock with a $29.00 price target.
Wave Life Sciences (WVE)
In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Wave Life Sciences. The company’s shares closed last Thursday at $15.36, close to its 52-week high of $16.74.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
Wave Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $32.57, implying a 123.4% upside from current levels. In a report issued on February 12, Wells Fargo also maintained a Buy rating on the stock with a $27.00 price target.
